MX2022015042A - Composiciones de trem y métodos relacionados con las mismas. - Google Patents

Composiciones de trem y métodos relacionados con las mismas.

Info

Publication number
MX2022015042A
MX2022015042A MX2022015042A MX2022015042A MX2022015042A MX 2022015042 A MX2022015042 A MX 2022015042A MX 2022015042 A MX2022015042 A MX 2022015042A MX 2022015042 A MX2022015042 A MX 2022015042A MX 2022015042 A MX2022015042 A MX 2022015042A
Authority
MX
Mexico
Prior art keywords
trem
compositions
methods relating
methods
trna
Prior art date
Application number
MX2022015042A
Other languages
English (en)
Inventor
Neil Kubica
Theonie Anastassiadis
Qingyi Li
David Charles Donnell Butler
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MX2022015042A publication Critical patent/MX2022015042A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Abstract

La divulgación se refiere en general a métodos para modular un parámetro de producción de un ARN correspondiente a, o un polipéptido codificado por, una secuencia de ácido nucleico que comprende un ORF endógeno que tiene un codón de terminación prematura, que comprende administrar una molécula efectora basada en ARNt que tiene una modificación de origen no natural.
MX2022015042A 2020-05-29 2021-05-28 Composiciones de trem y métodos relacionados con las mismas. MX2022015042A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031941P 2020-05-29 2020-05-29
PCT/US2021/034999 WO2021243290A1 (en) 2020-05-29 2021-05-28 Trem compositions and methods relating thereto

Publications (1)

Publication Number Publication Date
MX2022015042A true MX2022015042A (es) 2023-03-09

Family

ID=76797080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015042A MX2022015042A (es) 2020-05-29 2021-05-28 Composiciones de trem y métodos relacionados con las mismas.

Country Status (10)

Country Link
US (1) US20230203510A1 (es)
EP (1) EP4158031A1 (es)
JP (1) JP2023527413A (es)
KR (1) KR20230029685A (es)
CN (1) CN116018405A (es)
AU (1) AU2021278984A1 (es)
CA (1) CA3180101A1 (es)
IL (1) IL298539A (es)
MX (1) MX2022015042A (es)
WO (1) WO2021243290A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023009547A1 (en) * 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
TW202325313A (zh) * 2021-10-13 2023-07-01 美商旗艦先鋒創新公司 Ｔｒｅｍ組合物及使用方法
CN117138048B (zh) * 2023-10-30 2024-02-02 中山大学中山眼科中心 Dock6在制备防治眼部新生血管性疾病药物中的应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US99823A (en) 1870-02-15 Improved indigo soap
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
NZ592917A (en) 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
JP4380411B2 (ja) 2004-04-30 2009-12-09 澁谷工業株式会社 滅菌方法
KR101366482B1 (ko) 2004-12-27 2014-02-21 사일런스 테라퓨틱스 아게 코팅된 지질 복합체 및 이들의 용도
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7451428B2 (en) 2005-02-24 2008-11-11 Texas Instruments Incorporated Merging sub-resolution assist features of a photolithographic mask through the use of a merge bar
GB0600948D0 (en) * 2006-01-18 2006-02-22 Univ Dundee Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders
JP2009534690A (ja) 2006-07-10 2009-09-24 メムシック，インコーポレイテッド 磁場センサーを用いて偏揺れを感知するためのシステム、および、前記システムを用いた携帯用の電子装置
CA3044134A1 (en) 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US8168775B2 (en) 2008-10-20 2012-05-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
MX2011004859A (es) 2008-11-07 2011-08-03 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US8722082B2 (en) 2008-11-10 2014-05-13 Tekmira Pharmaceuticals Corporation Lipids and compositions for the delivery of therapeutics
CA2743139C (en) 2008-11-10 2019-04-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
EP2506879A4 (en) 2009-12-01 2014-03-19 Protiva Biotherapeutics Inc PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011090965A1 (en) 2010-01-22 2011-07-28 Merck Sharp & Dohme Corp. Novel cationic lipids for oligonucleotide delivery
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
JP4782232B1 (ja) 2010-04-09 2011-09-28 シャープ株式会社 光源モジュール、及びそれを備えた電子機器
CA2799091A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
KR101967411B1 (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
WO2011153120A1 (en) 2010-06-04 2011-12-08 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9676810B2 (en) * 2010-07-08 2017-06-13 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012031046A2 (en) 2010-08-31 2012-03-08 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna
MX349088B (es) 2010-09-20 2017-07-10 Merck Sharp & Dohme Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos.
AU2011307277A1 (en) 2010-09-30 2013-03-07 Merck Sharp & Dohme Corp. Low molecular weight cationic lipids for oligonucleotide delivery
CA2813024A1 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
US9617461B2 (en) 2010-12-06 2017-04-11 Schlumberger Technology Corporation Compositions and methods for well completions
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2012162210A1 (en) 2011-05-26 2012-11-29 Merck Sharp & Dohme Corp. Ring constrained cationic lipids for oligonucleotide delivery
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
NZ747501A (en) 2011-10-27 2020-05-29 Massachusetts Inst Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
EP2781507B1 (en) 2011-11-18 2017-03-22 Nof Corporation Cationic lipid having improved intracellular kinetics
CA2856737C (en) 2011-12-07 2023-09-26 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
DK3988537T1 (da) 2011-12-07 2022-05-23 Alnylam Pharmaceuticals Inc Bionedbrydelige lipider til afgivelse af aktive midler
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
EP3473611B1 (en) 2012-02-24 2021-10-20 Arbutus Biopharma Corporation Trialkyl cationic lipids and methods of use thereof
DK2830594T3 (en) 2012-03-27 2018-08-13 Sirna Therapeutics Inc DIETHER-BASED BIOLOGICALLY DEGRADABLE CATIONIC LIPIDS FOR siRNA RELEASE
JP6352950B2 (ja) 2013-03-08 2018-07-04 ノバルティス アーゲー 活性薬物の送達のための脂質と脂質組成物
CN105555757A (zh) 2013-07-23 2016-05-04 普洛体维生物治疗公司 用于递送信使rna的组合物和方法
EA201690576A1 (ru) 2013-10-22 2016-10-31 Шир Хьюман Дженетик Терапис, Инк. Липидные композиции для доставки матричной рнк
KR102095085B1 (ko) 2013-11-18 2020-03-31 아크투루스 쎄라퓨틱스, 인크. Rna 전달을 위한 이온화가능한 양이온성 지질
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
WO2015095340A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3083579B1 (en) 2013-12-19 2022-01-26 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
ES2931832T3 (es) 2014-06-25 2023-01-03 Acuitas Therapeutics Inc Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos
WO2016115632A1 (en) * 2015-01-21 2016-07-28 Exerkine Corporation Method for treating mitochondrial disease
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3316862A4 (en) 2015-07-02 2019-02-06 University of Louisville Research Foundation, Inc. COMPOSITIONS OF MICROVESICLES DERIVED FROM A PLANT FOR THE ADMINISTRATION OF ARNMI AND CANCER TREATMENT METHODS
EP4286012A2 (en) 2015-09-17 2023-12-06 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
HUE061564T2 (hu) 2015-10-28 2023-07-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske készítmények nukleinsavak bevitelére
JP7080172B2 (ja) 2015-12-10 2022-06-03 モデルナティエックス インコーポレイテッド 治療薬の送達のための組成物及び方法
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2017207738A1 (en) 2016-01-11 2018-07-12 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cancer indications
WO2017173054A1 (en) 2016-03-30 2017-10-05 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
JP7080826B2 (ja) 2016-05-16 2022-06-06 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質
WO2017223135A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Lipid nanoparticles
US20190161730A1 (en) 2016-07-07 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
EP3532103A1 (en) 2016-10-26 2019-09-04 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
MX2019006423A (es) 2016-12-02 2019-08-22 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas de celulas para penetrar en tumores solidos.
SG11201906933SA (en) 2017-02-17 2019-09-27 Rubius Therapeutics Inc Functionalized erythroid cells
EP3622079A1 (en) 2017-05-08 2020-03-18 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
JP2020537493A (ja) 2017-09-08 2020-12-24 ジェネレーション バイオ カンパニー 非ウイルス性カプシド不含ｄｎａベクターの脂質ナノ粒子製剤
EP3688162B1 (en) 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
EP3687581A1 (en) 2017-09-29 2020-08-05 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
KR20210023830A (ko) 2018-05-11 2021-03-04 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
EA202190736A1 (ru) * 2018-09-26 2021-09-16 Кейс Вестерн Ризерв Юниверсити Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
JP2022505234A (ja) 2018-10-18 2022-01-14 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
SG11202107206RA (en) * 2019-01-18 2021-08-30 Flagship Pioneering Inc Trem compositions and uses thereof
KR20220005039A (ko) 2019-04-25 2022-01-12 인텔리아 테라퓨틱스, 인크. 이온화 가능한 아민 지질 및 지질 나노입자
US20220228147A1 (en) * 2019-05-31 2022-07-21 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools
MX2022005362A (es) * 2019-11-04 2022-09-23 Flagship Pioneering Inc Composiciones de trem para codones con-raros y usos relacionados.

Also Published As

Publication number Publication date
WO2021243290A1 (en) 2021-12-02
KR20230029685A (ko) 2023-03-03
AU2021278984A1 (en) 2022-11-17
JP2023527413A (ja) 2023-06-28
CN116018405A (zh) 2023-04-25
EP4158031A1 (en) 2023-04-05
CA3180101A1 (en) 2021-12-02
US20230203510A1 (en) 2023-06-29
IL298539A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
MX2022015042A (es) Composiciones de trem y métodos relacionados con las mismas.
CR20200210A (es) Promotor especìfico de las cèlulas del epitelio pigmentario retinal en primates
MX2020005648A (es) Synp61, un promotor especifico de celulas del epitelio pigmentario retiniano de primates.
PH12018501628A1 (en) Optimized factor viii genes
MX2022013255A (es) Constructos de arn y usos de los mismos.
WO2021257730A3 (en) Cells modified by a cas12i polypeptide
MY191029A (en) Novel polypeptide and method of producing imp using the same
MX2022007858A (es) Polipeptidos efectores crispr-cas y metodos de uso de estos.
WO2007144190A3 (en) Plants with modulated expression of nac transcription factors having enhanced yield-related traits and a method for making the same
AU2019204119B2 (en) Novel polypeptide and method of producing IMP using the same
MX2022005328A (es) Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
MX2020006619A (es) Segmentos de liberacion y composiciones vinculantes que comprenden los mismos.
AU2008220715A8 (en) Plants having enhanced yield-related traits and a method for making the same
SI1670779T1 (sl) Postopki za pripravo 3-metilamino-1-(tien-2-il)-propan ola
WO2020223514A3 (en) Novel omni-50 crispr nuclease
TW200512292A (en) Fungal immunomodulatory protein (FIP) prepared by microorganisms and uses thereof
NZ595231A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
MX2017007503A (es) Metodos novedosos para conjugacion de polipeptido mediada por enzimas usando sortasa.
KR20180084352A (ko) 돌돔 유래의 신규한 피스시딘 펩티드 및 이의 용도
WO2019229064A3 (en) Method for producing albicanol compounds
WO2021231808A3 (en) Compositions and methods for treating gjb2-associated hearing loss
MY159849A (en) Mammalian expression vector
WO2023130022A3 (en) Cystatin rna compositions for tissue engineering
MX2020010422A (es) Alfa-amilasa maltogenica variante.
DE602005020339D1 (de) Pntr transkriptionsfaktor knock-out und dessen verwendungen